Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PFKFB4 | Q16877 | 1/20 | 0.33 |
| ▸ | CHEK1 | O14757 | 4/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.31 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.31 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.31 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.31 |
| ▸ | FLT3 | P36888 | 1/20 | 0.31 |
| ▸ | BLK | P51451 | 1/20 | 0.31 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.31 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.31 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.31 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3483793 | 0.99 | PFKFB4 (0.33) | PFKFB4CHEK1KCNH2NUAK1CHEK2 | |
| Trifluoroacetic Acid SCHEMBL3484096 | 0.94 | CACNA1B (0.34) | PFKFB4PFKFB3 | |
| SCHEMBL3483565 | 0.86 | TRPV4 (0.32) | — | |
| Hydrochloric Acid SCHEMBL3483594 | 0.85 | TRPV4 (0.31) | — | |
| SCHEMBL3483637 | 0.82 | TRPV4 (0.32) | PFKFB4PFKFB3 | |
| SCHEMBL13032371 | 0.82 | CHEK1 (0.30) | CHEK1KCNH2NUAK1CHEK2RPS6KB1 | |
| Trifluoroacetic Acid SCHEMBL3480474 | 0.82 | CACNA1B (0.32) | PFKFB4PFKFB3 | |
| SCHEMBL14931203 | 0.79 | CHEK1 (0.30) | CHEK1KCNH2NUAK1CHEK2RPS6KB1 | |
| Trifluoroacetic Acid SCHEMBL3480462 | 0.78 | PFKFB4 (0.31) | PFKFB4PFKFB3 | |
| SCHEMBL3483361 | 0.77 | TRPV4 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2049200-B1 | NOVEL INHIBITORS OF BETA-LACTAMASE | METHYLGENE INC (CA) | 2015-04-29 | — | — | EP | claimed |
| US-8440643-B2 | Inhibitors of beta-lactamase | METHYLGENE INC. (CA) | 2013-05-14 | — | — | US | claimed |
| US-20100279983-A1 | NOVEL INHIBITORS OF BETA-LACTAMASE | METHYLGENE INC. | 2010-11-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100279983-A1 | NOVEL INHIBITORS OF BETA-LACTAMASE | MGAM, MGAM2, PGLS | PFKFB4 577/4885CHEK1 3556/4885KCNH2 1960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.